Cyclin-dependent kinase inhibitor 1A gene promoter (CDKN1A promoter)

The CDKN1A gene promoter is a critical regulatory region of the human genome that controls the expression of the p21 protein, a potent cyclin-dependent kinase inhibitor (NCBI Gene, 2015). This locus integrates signals from various stress-response pathways, most notably the p53 tumor suppressor pathway, to regulate the transition from the G1 to the S phase of the cell cycle (UniProt, 2024). In many pathological states, particularly cancer, the CDKN1A promoter is often silenced or downregulated, leading to unchecked cell proliferation and genomic instability (MDPI, 2024). Therapeutic targeting of this locus focuses on restoring or enhancing p21 expression to induce cell cycle arrest, senescence, or apoptosis in diseased cells (Patsnap, 2024). Modern pharmacological approaches include the use of small activating RNAs (saRNAs) like RAG-01 that specifically target the promoter sequence to trigger transcriptional activation (Ractigen Therapeutics, 2024). While upregulating CDKN1A is a promising strategy for tumor suppression, challenges include the potential for inducing chronic senescence and the dual role of p21, which can promote drug resistance when localized to the cytoplasm (NIH, 2015).

Other names

p21 promoterCIP1 promoterWAF1 promoterSDI1 promoterCAP20 promoterCDKN1A locusp21 gene promoter

Transcriptional activation via RNA activation (RNAa), epigenetic modulation (e.g., histone deacetylation inhibition), and p53-mediated transactivation.